In Just One Dose

MIT's Tech Review reports on Alnylam's RNAi-based drug that, with one dose, lowers cholesterol by up to 60 percent in rodents and monkeys. The drug targets PCSK9, an enzyme that had been shown to affect LDL levels and people's risk of heart disease. The RNAi drug was bundled into lipid-based nanoparticles to be transported to the liver once injected. This drug, says the article, could be used in conjunction with statins to get LDL levels even lower.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.